Sign In
Buy LEXX
$0.583
+0.0426 (+7.89%)
At Close: Jun 22, 2026
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
09:25am, Wednesday, 17'th Jun 2026
More People Than Ever Taking GLP-1 Drugs for Weight Loss Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand
09:25am, Wednesday, 17'th Jun 2026
More people than ever taking GLP-1 drugs for weight loss Growing list of diseases now indicated as treatable with GLP-1 drugs
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.
09:25am, Tuesday, 09'th Jun 2026
Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ Kelowna, British Columbia - June 9 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NA
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
09:25am, Tuesday, 09'th Jun 2026
Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lex
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
09:25am, Wednesday, 03'rd Jun 2026
KELOWNA, BC / ACCESS Newswire / June 3, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it is attending t
Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program
09:25am, Wednesday, 03'rd Jun 2026
Kelowna, British Columbia - June 3 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , announces
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
09:15am, Tuesday, 19'th May 2026
KELOWNA, BC / ACCESS Newswire / May 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that ethi
Lexaria Bioscience Releases Second Episode of Investor Video Series
09:25am, Thursday, 07'th May 2026
CEO Rich Christopher Discusses Recently Announced Material Transfer Agreement Extension and 2026 Research Priorities Kelowna, British Columbia – May 7, 2026 - TheNewswire - Lexaria Bioscience Cor
Lexaria Updates Progress on Human Study #7
09:10am, Tuesday, 05'th May 2026
KELOWNA, BC / ACCESS Newswire / May 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pil
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
09:25am, Friday, 01'st May 2026
Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy KELOWNA, BC / ACCESS Newswire / May 1, 2026 / Lexaria Bioscience Corp. (NASDAQ
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
09:10am, Wednesday, 29'th Apr 2026
KELOWNA, BC / ACCESS Newswire / April 29, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Ma
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
09:05am, Thursday, 23'rd Apr 2026
Contracts signed for Animal Study #2: GLP-1-A26-2 Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (N
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
09:10am, Tuesday, 21'st Apr 2026
600,000 New Wegovy® Pill Prescriptions Written in First Two Months Kelowna, British Columbia – April 21, 2026 - TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
09:10am, Wednesday, 15'th Apr 2026
Contracts signed for Animal Study GLP-1-A26-1 KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
09:10am, Tuesday, 07'th Apr 2026
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Na
